Ratings by Canaccord (Bill Maughan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/29/2025 | Merus N.V. | MRUS | Downgrade | Hold (Buy) |
68.89 (90.00) |
30.64% | Details | |
| 6/4/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Nkarta Inc. | NKTX | Maintain | Buy (N/A) |
|
Details | ||
| 5/10/2024 | Fate Therapeutics | FATE | Maintain | Buy (N/A) |
|
Details | ||
| 5/9/2024 | Immunocore Holdings | IMCR | Maintain | Hold (N/A) |
|
Details | ||
| 5/3/2024 | Moderna | MRNA | Maintain | Hold (N/A) |
|
Details | ||
| 3/27/2024 | Delcath Systems | DCTH | Maintain | Buy (N/A) |
|
Details | ||
| 3/26/2024 | Nkarta Inc. | NKTX | Maintain | Buy (N/A) |
|
Details | ||
| 3/15/2024 | Century Therapeutics | IPSC | Maintain | Buy (N/A) |
|
Details | ||
| 3/1/2024 | Merus N.V. | MRUS | Maintain | Buy (N/A) |
|
Details | ||
| 2/29/2024 | Immunocore Holdings | IMCR | Maintain | Hold (N/A) |
|
Details | ||
| 2/27/2024 | Fate Therapeutics | FATE | Maintain | Buy (N/A) |
|
Details | ||
| 2/23/2024 | Moderna | MRNA | Maintain | Hold (N/A) |
|
Details | ||
| 2/22/2024 | Theratechnologies Inc. | THTX | Maintain | Hold (N/A) |
|
Details | ||
| 11/29/2023 | Moderna | MRNA | New Coverage | Hold (N/A) |
77.72 (52.52) |
-32.42% | Details | |
| 11/2/2023 | Merus N.V. | MRUS | New Coverage | Buy (N/A) |
20.11 (68.89) |
242.57% | Details | |
| 10/17/2023 | Nkarta Inc. | NKTX | Maintain | Buy (N/A) |
|
Details | ||
| 7/17/2023 | Immunocore Holdings | IMCR | New Coverage | Hold (N/A) |
63.40 (32.94) |
-48.04% | Details | |
| 7/3/2023 | Theratechnologies Inc. | THTX | New Coverage | Hold (N/A) |
0.84 (3.39) |
303.57% | Details | |
| 10/11/2022 | Nkarta Inc. | NKTX | New Coverage | Buy (N/A) |
13.52 (2.50) |
-81.51% | Details | |
| 10/11/2022 | Fate Therapeutics | FATE | New Coverage | Buy (N/A) |
21.32 (1.33) |
-93.76% | Details | |
| 10/11/2022 | Century Therapeutics | IPSC | New Coverage | Buy (N/A) |
9.32 (2.56) |
-72.53% | Details |
